Pharmaceutical Executive

By Pharmaceutical Executive PodcastScience Life Sciences

Pharmaceutical Executive episodes

May 29 Pharmaceutical Executive Daily: WHO Identifies Priority Treatment Candidates for Ebola
In today’s Pharmaceutical Executive Daily, Harpreet Singh discusses the evolving regulatory landscape for biopharma, the World Health Organization identifies three priority treatment candidates for the Bundibugyo strain of Ebola virus disease, and this week’s pharma roundup highlights new findings on Mounjaro and long COVID-related immune system changes.
3 min
May 28 Pharmaceutical Executive Daily: CVS Health to Offer Zepbound and Foundayo
In today’s Pharmaceutical Executive Daily, an FDA advisory committee weighs recommendations for the composition of the 2026–2027 Covid-19 vaccines, CVS Health restores coverage for Eli Lilly’s Zepbound while adding the company’s newly approved obesity pill Foundayo, and experts discuss how treatment expectations are evolving in lupus care.
3 min
May 26 Pharmaceutical Executive Daily: FDA Approves Hepcludex
In today’s Pharmaceutical Executive Daily, Eli Lilly announces three acquisitions totaling roughly $3 billion, the FDA approves Hepcludex as the first treatment for chronic hepatitis delta virus infection in the United States, and biotech finance leaders reflect on the lessons learned from navigating two decades of volatile markets.
3 min
May 22 Pharmaceutical Executive Daily: FDA Approves Datroway
3 min
May 21 Pharmaceutical Executive Daily: What It Takes to Move Machine Learning
In today's Pharmaceutical Executive Daily, Reuters reports that lower-priced oral GLP-1 pills from Eli Lilly and Novo Nordisk are drawing patients away from compounded weight loss medications, Gilead Sciences' renews its five-year collaboration with WHO and Johnson and Johnson’s collaboration with the Department of Health Abu Dhabi, finally Partha Anbil argues that truly industrializing machine learning and AI in life sciences requires systems that are scientifically credible, clinically defensible, regulatorily traceable, and operationally sustained.
4 min
May 20 Pharmaceutical Executive Daily: Eli Lilly Acquires Engage Bio
In today's Pharmaceutical Executive Daily, Eli Lilly announces a deal worth up to $202 million for Engage Biologics and its preclinical non-viral DNA delivery platform, two significant deals including Bristol Myers Squibb's enterprise-wide agreement to deploy Claude across its global operations and Incyte's expanded molecular AI collaboration with Genesis, and FDA grants two new early-stage breast cancer indications to Enhertu, marking trastuzumab deruxtecan's entry into the curative-intent setting for the first time.
4 min
May 19 Pharmaceutical Executive Daily: TrumpRx Expands to Offer Over 600 Generic Drugs
In today’s Pharmaceutical Executive Daily, the Trump administration expands TrumpRx to include more than 600 generic medicines, industry leaders rethink pharma’s traditional go-to-market model, and a biotech funding roundup highlights continued investment in early-stage therapeutics and radiopharmaceutical development.
3 min
May 19 Rethinking Pharma's Go-to-Market Formula
In this episode of the Pharm Exec podcast, Mike Petroutsas, president and head of U.S. commercial at Astellas, shares the secrets to building a more agile commercial operating model — and mindset — equipped for today’s evolving engagement landscape. Drawing on examples from GI oncology, retina care, and women’s health, Petroutsas joins Mike Christel, group managing editor, MJH Life Sciences, to discuss how Astellas is tapping real-world insights, social listening and internal collaboration to refine commercialization efforts and boost patient and physician engagement.
The PhRMA board member also offers perspective on commercial strategy implications from the Inflation Reduction Act and other healthcare policy, and touches as well on the career leadership lessons that guide his approach today.
22 min
May 18 Pharmaceutical Executive Daily: FDA Approves Baxdrostat
3 min
May 15 Pharmaceutical Executive Daily: FDA Approves AstraZeneca's Fasenra
In today's Pharmaceutical Executive Daily, FDA approves AstraZeneca's Fasenra as a new treatment for hypereosinophilic syndrome in patients 12 years and older, the FDA places a full clinical hold on Aardvark Therapeutics' ARD-101 program, and BeOne Medicines co-founder and CEO John Oyler touches on building an oncology powerhouse from a disruptive idea and playing the long game on speed, science, and scale.
4 min